GPR158, a member of the G protein-coupled receptor (GPCR) family, represents a class of proteins that play pivotal roles in cellular signal transduction and physiological regulation. Unlike classical GPCRs that transduce extracellular signals through membrane-spanning domains, GPR158's role extends beyond traditional GPCR functions, implicating it in a variety of biological processes including neural development, stress response, and the regulation of intraocular pressure. It operates through complex signaling cascades, influencing both intracellular pathways and intercellular communications. The protein's expression patterns and functional implications suggest its involvement in the fine-tuning of cellular responses to environmental stimuli, thereby contributing to the maintenance of cellular homeostasis and the modulation of physiological states. Its unique structural and functional attributes underscore the intricate regulatory mechanisms that define cellular responsiveness and adaptability.
The inhibition of GPR158 involves targeting its signaling pathways to alter the downstream effects mediated by this receptor. Given its integral role in various signaling cascades, inhibiting GPR158 can disrupt the normal physiological processes it regulates. Mechanisms of inhibition typically focus on the attenuation of GPR158's ability to interact with its associated G proteins or other signaling molecules, thereby hindering its signal transduction capabilities. This can be achieved through direct interaction with the receptor, interfering with its ligand-binding domain, or through more indirect approaches that modulate its expression levels or post-translational modifications. Additionally, the blockade of downstream effectors in the GPR158 signaling pathway represents another strategy for inhibiting its functional outcomes. These approaches aim to reduce the receptor's regulatory impact on cellular processes, illustrating the complex interplay between receptor activity, signaling specificity, and physiological regulation. Understanding the nuances of GPR158 inhibition sheds light on the broader implications of GPCR signaling in cellular function and homeostasis.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
A non-selective beta-adrenergic receptor antagonist known to modulate GPCR activity. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $122.00 $235.00 $520.00 $979.00 $1500.00 | 2 | |
A non-selective beta-adrenergic blocker with alpha-1 blocking activity; influences GPCR signaling. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
An angiotensin II receptor antagonist that affects GPCR-mediated pathways. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $50.00 $168.00 $520.00 | 2 | |
An alpha-2 adrenergic receptor blocker that can alter GPCR-related signaling. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
A long-acting beta2-adrenergic agonist that acts on GPCR pathways. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
A dopamine receptor antagonist which can influence various GPCR-mediated pathways. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $200.00 | 2 | |
A muscarinic acetylcholine receptor antagonist that affects GPCR signaling. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $176.00 | ||
A mixed alpha/beta adrenergic antagonist that modifies GPCR signaling. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $80.00 $326.00 | 1 | |
A serotonin 5-HT3 receptor antagonist that can affect GPCR-related processes. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
A calcium channel blocker that indirectly affects GPCR activity by modulating intracellular calcium levels. |